Navigating TYK-2 Inhibitor Use for Psoriasis Maintenance and Long-Term Benefits

Panelists:

Linda Stein-Gold, MD

Henry Ford Health

Detroit, Michigan

Mona Shahriari, MD

Yale University

New Haven, Connecticut

Micheal Cameron, MD, FAAD

Cameron Dermatology

New York, New York

Leon Kircik, MD

DermResearch, PLLC

Louisville, Kentucky

George Han, MD

Hofstra University

Long Island, New York

Program Description:

Experts in the management of skin conditions discuss the latest developments in plaque psoriasis management, covering emerging oral therapies, novel topical treatments, and advancements in biologic therapy. The discussion provides practical insights for healthcare professionals to integrate these innovations into daily clinical practice for optimal patient outcomes. Additionally, the panel addresses the strategic placement of emerging therapies within current treatment guidelines, ensuring participants stay informed about the evolving landscape of psoriasis care.

Segment Description:

Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.